開能健康(300272.SZ):聘任劉文軍擔任公司財務總監
格隆匯5月30日丨開能健康(300272.SZ)公佈,近日,公司董事會收到公司財務總監袁學偉提交的書面辭職報吿,袁學偉因工作調動的原因辭去公司財務總監職務及代行的董事會祕書職責。根據《公司法》和《公司章程》等相關規定,袁學偉提交的辭職報吿自送達董事會之日起生效。
經公司總經理提名,提名委員會審核,公司董事會同意聘任劉文軍擔任公司財務總監,任期自本次董事會審議通過之日起至第五屆董事會屆滿之日止。
經公司董事長提名,提名委員會審核,公司董事會同意聘任徐延茂擔任公司董事會祕書,任期自本次董事會審議通過之日起至第五屆董事會屆滿之日止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.